Drug Trial Radar · NCT03606395
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Last checked: Nov 19, 2026Latest source record: Jul 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Jun 6, 2018
Primary completion
Jun 9, 2019
Study completion Jul 7, 2019
Sponsor
- Lead sponsor
- Navitor Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Randomized, two-part, placebo-controlled study of single ascending doses of NV-5138 in healthy volunteers, and a single dose of NV-5138 in subjects with Treatment-Resistant Depression (TRD)
Conditions
- Treatment Resistant Depression
Interventions
NV-5138Drug
single ascending dose
PlacebosDrug
Placebo liquid solution to mimic NV-5138
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-related adverse events as evidenced by CTCAE v.5.0Time frame: Baseline through Day 9
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Collaborative Neuroscience Network
Long Beach, California
Synergy San Diego
San Diego, California
MD Clinical
Hallandale, Florida
Innovative Clinical Research Inc
Hialeah, Florida
Research Centers of America
Hollywood, Florida
St. Louis Clinical Trials
St Louis, Missouri
Hassman Research Institute
Berlin, New Jersey
Midwest Clinical Research
Dayton, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.